April 28, 2023 by admin aurigene Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers
April 28, 2023 by admin aurigene Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)
April 27, 2023 by admin aurigene In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
April 27, 2023 by admin aurigene Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
April 27, 2023 by admin aurigene Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
April 27, 2023 by admin aurigene An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity
